CULLINAN THERAPEUTICS INC (CGEM) Stock Fundamental Analysis

NASDAQ:CGEM • US2300311063

13.65 USD
-0.23 (-1.66%)
At close: Feb 20, 2026
13.51 USD
-0.14 (-1.03%)
After Hours: 2/20/2026, 8:22:34 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall CGEM gets a fundamental rating of 3 out of 10. We evaluated CGEM against 521 industry peers in the Biotechnology industry. CGEM has a great financial health rating, but its profitability evaluates not so good. CGEM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CGEM had negative earnings in the past year.
  • CGEM had a negative operating cash flow in the past year.
  • In the past 5 years CGEM reported 4 times negative net income.
  • In the past 5 years CGEM always reported negative operating cash flow.
CGEM Yearly Net Income VS EBIT VS OCF VS FCFCGEM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -44.78%, CGEM is in line with its industry, outperforming 54.70% of the companies in the same industry.
  • With a decent Return On Equity value of -48.03%, CGEM is doing good in the industry, outperforming 67.56% of the companies in the same industry.
Industry RankSector Rank
ROA -44.78%
ROE -48.03%
ROIC N/A
ROA(3y)-12.91%
ROA(5y)-15.57%
ROE(3y)-13.78%
ROE(5y)-16.56%
ROIC(3y)N/A
ROIC(5y)N/A
CGEM Yearly ROA, ROE, ROICCGEM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

  • CGEM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGEM Yearly Profit, Operating, Gross MarginsCGEM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, CGEM has more shares outstanding
  • CGEM has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for CGEM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CGEM Yearly Shares OutstandingCGEM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CGEM Yearly Total Debt VS Total AssetsCGEM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 12.59 indicates that CGEM is not in any danger for bankruptcy at the moment.
  • CGEM has a Altman-Z score of 12.59. This is amongst the best in the industry. CGEM outperforms 84.07% of its industry peers.
  • CGEM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.59
ROIC/WACCN/A
WACCN/A
CGEM Yearly LT Debt VS Equity VS FCFCGEM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • CGEM has a Current Ratio of 10.45. This indicates that CGEM is financially healthy and has no problem in meeting its short term obligations.
  • CGEM's Current ratio of 10.45 is amongst the best of the industry. CGEM outperforms 83.11% of its industry peers.
  • A Quick Ratio of 10.45 indicates that CGEM has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 10.45, CGEM belongs to the top of the industry, outperforming 83.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.45
Quick Ratio 10.45
CGEM Yearly Current Assets VS Current LiabilitesCGEM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • CGEM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.55%.
EPS 1Y (TTM)-16.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -0.06% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-18.87%
EPS Next 2Y-2.38%
EPS Next 3Y2.38%
EPS Next 5Y-0.06%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CGEM Yearly Revenue VS EstimatesCGEM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
CGEM Yearly EPS VS EstimatesCGEM Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • CGEM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGEM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGEM Price Earnings VS Forward Price EarningsCGEM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGEM Per share dataCGEM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.38%
EPS Next 3Y2.38%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CGEM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CULLINAN THERAPEUTICS INC

NASDAQ:CGEM (2/20/2026, 8:22:34 PM)

After market: 13.51 -0.14 (-1.03%)

13.65

-0.23 (-1.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-05
Inst Owners106.68%
Inst Owner Change0.84%
Ins Owners1.14%
Ins Owner Change-0.17%
Market Cap806.44M
Revenue(TTM)N/A
Net Income(TTM)-216.81M
Analysts87.06
Price Target32.92 (141.17%)
Short Float %14.18%
Short Ratio9.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.4%
Min EPS beat(2)-25.93%
Max EPS beat(2)21.14%
EPS beat(4)3
Avg EPS beat(4)2.55%
Min EPS beat(4)-25.93%
Max EPS beat(4)21.14%
EPS beat(8)6
Avg EPS beat(8)10.58%
EPS beat(12)9
Avg EPS beat(12)6.33%
EPS beat(16)11
Avg EPS beat(16)5.8%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.23%
PT rev (3m)22.55%
EPS NQ rev (1m)-2.03%
EPS NQ rev (3m)4.24%
EPS NY rev (1m)-0.04%
EPS NY rev (3m)6.3%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.79
P/tB 1.79
EV/EBITDA N/A
EPS(TTM)-3.31
EYN/A
EPS(NY)-3.18
Fwd EYN/A
FCF(TTM)-2.95
FCFYN/A
OCF(TTM)-2.95
OCFYN/A
SpS0
BVpS7.64
TBVpS7.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.78%
ROE -48.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-12.91%
ROA(5y)-15.57%
ROE(3y)-13.78%
ROE(5y)-16.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.3%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.45
Quick Ratio 10.45
Altman-Z 12.59
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)440.88%
Cap/Depr(5y)267.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.59%
EPS Next Y-18.87%
EPS Next 2Y-2.38%
EPS Next 3Y2.38%
EPS Next 5Y-0.06%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.8%
EBIT Next 3Y5.52%
EBIT Next 5YN/A
FCF growth 1Y-22.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.49%
OCF growth 3YN/A
OCF growth 5YN/A

CULLINAN THERAPEUTICS INC / CGEM FAQ

What is the fundamental rating for CGEM stock?

ChartMill assigns a fundamental rating of 3 / 10 to CGEM.


What is the valuation status for CGEM stock?

ChartMill assigns a valuation rating of 0 / 10 to CULLINAN THERAPEUTICS INC (CGEM). This can be considered as Overvalued.


Can you provide the profitability details for CULLINAN THERAPEUTICS INC?

CULLINAN THERAPEUTICS INC (CGEM) has a profitability rating of 1 / 10.


Can you provide the financial health for CGEM stock?

The financial health rating of CULLINAN THERAPEUTICS INC (CGEM) is 8 / 10.